nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA2A—type 2 diabetes mellitus	0.4	1	CbGaD
Apraclonidine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.108	0.309	CbGbCtD
Apraclonidine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.103	0.293	CbGbCtD
Apraclonidine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0716	0.204	CbGbCtD
Apraclonidine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0686	0.195	CbGbCtD
Apraclonidine—Lofexidine—ADRA2A—type 2 diabetes mellitus	0.00149	0.306	CrCbGaD
Apraclonidine—Brimonidine—ADRA2A—type 2 diabetes mellitus	0.000959	0.197	CrCbGaD
Apraclonidine—Tizanidine—ADRA2A—type 2 diabetes mellitus	0.000877	0.181	CrCbGaD
Apraclonidine—Tizanidine—CYP1A2—type 2 diabetes mellitus	0.000609	0.125	CrCbGaD
Apraclonidine—Clonidine—ADRA2A—type 2 diabetes mellitus	0.000428	0.0882	CrCbGaD
Apraclonidine—Clonidine—CYP1A2—type 2 diabetes mellitus	0.000297	0.0613	CrCbGaD
Apraclonidine—Clonidine—CYP3A4—type 2 diabetes mellitus	0.000197	0.0406	CrCbGaD
Apraclonidine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.00018	0.00111	CcSEcCtD
Apraclonidine—Chest pain—Orlistat—type 2 diabetes mellitus	0.00018	0.00111	CcSEcCtD
Apraclonidine—Myalgia—Orlistat—type 2 diabetes mellitus	0.00018	0.00111	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000179	0.0011	CcSEcCtD
Apraclonidine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000178	0.0011	CcSEcCtD
Apraclonidine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000178	0.00109	CcSEcCtD
Apraclonidine—Discomfort—Orlistat—type 2 diabetes mellitus	0.000178	0.00109	CcSEcCtD
Apraclonidine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000177	0.00109	CcSEcCtD
Apraclonidine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000176	0.00108	CcSEcCtD
Apraclonidine—Malaise—Metformin—type 2 diabetes mellitus	0.000176	0.00108	CcSEcCtD
Apraclonidine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000175	0.00108	CcSEcCtD
Apraclonidine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000175	0.00108	CcSEcCtD
Apraclonidine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000175	0.00107	CcSEcCtD
Apraclonidine—Syncope—Metformin—type 2 diabetes mellitus	0.000175	0.00107	CcSEcCtD
Apraclonidine—Oedema—Valsartan—type 2 diabetes mellitus	0.000174	0.00107	CcSEcCtD
Apraclonidine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000174	0.00107	CcSEcCtD
Apraclonidine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000174	0.00107	CcSEcCtD
Apraclonidine—Infection—Valsartan—type 2 diabetes mellitus	0.000173	0.00107	CcSEcCtD
Apraclonidine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000173	0.00106	CcSEcCtD
Apraclonidine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000173	0.00106	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000173	0.00106	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000173	0.00106	CcSEcCtD
Apraclonidine—Erythema—Losartan—type 2 diabetes mellitus	0.000173	0.00106	CcSEcCtD
Apraclonidine—Oedema—Orlistat—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Apraclonidine—Headache—Glipizide—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Apraclonidine—Palpitations—Metformin—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Apraclonidine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Apraclonidine—Infection—Orlistat—type 2 diabetes mellitus	0.000171	0.00105	CcSEcCtD
Apraclonidine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000171	0.00105	CcSEcCtD
Apraclonidine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000171	0.00105	CcSEcCtD
Apraclonidine—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.00017	0.00105	CcSEcCtD
Apraclonidine—Tension—Losartan—type 2 diabetes mellitus	0.00017	0.00104	CcSEcCtD
Apraclonidine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00017	0.00104	CcSEcCtD
Apraclonidine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000169	0.00104	CcSEcCtD
Apraclonidine—Nervousness—Losartan—type 2 diabetes mellitus	0.000168	0.00103	CcSEcCtD
Apraclonidine—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000168	0.00103	CcSEcCtD
Apraclonidine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000167	0.00103	CcSEcCtD
Apraclonidine—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000167	0.00103	CcSEcCtD
Apraclonidine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000166	0.00102	CcSEcCtD
Apraclonidine—Myalgia—Metformin—type 2 diabetes mellitus	0.000166	0.00102	CcSEcCtD
Apraclonidine—Chest pain—Metformin—type 2 diabetes mellitus	0.000166	0.00102	CcSEcCtD
Apraclonidine—Malaise—Irbesartan—type 2 diabetes mellitus	0.000166	0.00102	CcSEcCtD
Apraclonidine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000165	0.00101	CcSEcCtD
Apraclonidine—Syncope—Irbesartan—type 2 diabetes mellitus	0.000165	0.00101	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000165	0.00101	CcSEcCtD
Apraclonidine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Apraclonidine—Discomfort—Metformin—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Apraclonidine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Apraclonidine—Nausea—Glipizide—type 2 diabetes mellitus	0.000163	0.001	CcSEcCtD
Apraclonidine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000163	0.001	CcSEcCtD
Apraclonidine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000163	0.001	CcSEcCtD
Apraclonidine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000163	0.000999	CcSEcCtD
Apraclonidine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000162	0.000998	CcSEcCtD
Apraclonidine—Pain—Gliclazide—type 2 diabetes mellitus	0.000162	0.000998	CcSEcCtD
Apraclonidine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000162	0.000993	CcSEcCtD
Apraclonidine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000161	0.00099	CcSEcCtD
Apraclonidine—Headache—Glimepiride—type 2 diabetes mellitus	0.000161	0.000988	CcSEcCtD
Apraclonidine—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.00016	0.000986	CcSEcCtD
Apraclonidine—Headache—Sitagliptin—type 2 diabetes mellitus	0.00016	0.000984	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000159	0.000977	CcSEcCtD
Apraclonidine—Oedema—Metformin—type 2 diabetes mellitus	0.000159	0.000977	CcSEcCtD
Apraclonidine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000158	0.000973	CcSEcCtD
Apraclonidine—Infection—Metformin—type 2 diabetes mellitus	0.000158	0.00097	CcSEcCtD
Apraclonidine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000158	0.00097	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000157	0.000966	CcSEcCtD
Apraclonidine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000157	0.000963	CcSEcCtD
Apraclonidine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000156	0.000962	CcSEcCtD
Apraclonidine—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000156	0.000962	CcSEcCtD
Apraclonidine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000156	0.000962	CcSEcCtD
Apraclonidine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000156	0.000959	CcSEcCtD
Apraclonidine—Malaise—Losartan—type 2 diabetes mellitus	0.000156	0.000958	CcSEcCtD
Apraclonidine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000156	0.000958	CcSEcCtD
Apraclonidine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000156	0.000958	CcSEcCtD
Apraclonidine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000156	0.000956	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000155	0.000955	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000155	0.000955	CcSEcCtD
Apraclonidine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000155	0.000953	CcSEcCtD
Apraclonidine—Syncope—Losartan—type 2 diabetes mellitus	0.000155	0.000953	CcSEcCtD
Apraclonidine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000155	0.000952	CcSEcCtD
Apraclonidine—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000155	0.00095	CcSEcCtD
Apraclonidine—Skin disorder—Metformin—type 2 diabetes mellitus	0.000154	0.000949	CcSEcCtD
Apraclonidine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000153	0.000944	CcSEcCtD
Apraclonidine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000153	0.00094	CcSEcCtD
Apraclonidine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000153	0.00094	CcSEcCtD
Apraclonidine—Palpitations—Losartan—type 2 diabetes mellitus	0.000153	0.000939	CcSEcCtD
Apraclonidine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000152	0.000936	CcSEcCtD
Apraclonidine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000152	0.000935	CcSEcCtD
Apraclonidine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000152	0.000933	CcSEcCtD
Apraclonidine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000152	0.000933	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000151	0.000926	CcSEcCtD
Apraclonidine—Fatigue—Valsartan—type 2 diabetes mellitus	0.00015	0.000925	CcSEcCtD
Apraclonidine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.00015	0.000923	CcSEcCtD
Apraclonidine—Oedema—Irbesartan—type 2 diabetes mellitus	0.00015	0.000922	CcSEcCtD
Apraclonidine—Pruritus—Glyburide—type 2 diabetes mellitus	0.00015	0.00092	CcSEcCtD
Apraclonidine—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000149	0.000917	CcSEcCtD
Apraclonidine—Constipation—Valsartan—type 2 diabetes mellitus	0.000149	0.000917	CcSEcCtD
Apraclonidine—Infection—Irbesartan—type 2 diabetes mellitus	0.000149	0.000916	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000149	0.000915	CcSEcCtD
Apraclonidine—Fatigue—Orlistat—type 2 diabetes mellitus	0.000149	0.000914	CcSEcCtD
Apraclonidine—Erythema—Ramipril—type 2 diabetes mellitus	0.000148	0.000911	CcSEcCtD
Apraclonidine—Pain—Orlistat—type 2 diabetes mellitus	0.000147	0.000906	CcSEcCtD
Apraclonidine—Myalgia—Losartan—type 2 diabetes mellitus	0.000147	0.000905	CcSEcCtD
Apraclonidine—Chest pain—Losartan—type 2 diabetes mellitus	0.000147	0.000905	CcSEcCtD
Apraclonidine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000147	0.000904	CcSEcCtD
Apraclonidine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000147	0.000904	CcSEcCtD
Apraclonidine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000146	0.000896	CcSEcCtD
Apraclonidine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000146	0.000895	CcSEcCtD
Apraclonidine—Tension—Ramipril—type 2 diabetes mellitus	0.000145	0.000894	CcSEcCtD
Apraclonidine—Discomfort—Losartan—type 2 diabetes mellitus	0.000145	0.000894	CcSEcCtD
Apraclonidine—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000145	0.000892	CcSEcCtD
Apraclonidine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000145	0.000891	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000145	0.00089	CcSEcCtD
Apraclonidine—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000145	0.00089	CcSEcCtD
Apraclonidine—Nervousness—Ramipril—type 2 diabetes mellitus	0.000144	0.000885	CcSEcCtD
Apraclonidine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000144	0.000885	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000143	0.000877	CcSEcCtD
Apraclonidine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000143	0.000877	CcSEcCtD
Apraclonidine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000142	0.000873	CcSEcCtD
Apraclonidine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000142	0.000871	CcSEcCtD
Apraclonidine—Somnolence—Metformin—type 2 diabetes mellitus	0.000141	0.000868	CcSEcCtD
Apraclonidine—Oedema—Losartan—type 2 diabetes mellitus	0.000141	0.000867	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000141	0.000867	CcSEcCtD
Apraclonidine—Infection—Losartan—type 2 diabetes mellitus	0.00014	0.000862	CcSEcCtD
Apraclonidine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00014	0.00086	CcSEcCtD
Apraclonidine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000138	0.000851	CcSEcCtD
Apraclonidine—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000138	0.000848	CcSEcCtD
Apraclonidine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000138	0.000846	CcSEcCtD
Apraclonidine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000137	0.000845	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000137	0.000843	CcSEcCtD
Apraclonidine—Fatigue—Metformin—type 2 diabetes mellitus	0.000137	0.000842	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000137	0.00084	CcSEcCtD
Apraclonidine—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000136	0.000838	CcSEcCtD
Apraclonidine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000136	0.000838	CcSEcCtD
Apraclonidine—Constipation—Metformin—type 2 diabetes mellitus	0.000136	0.000835	CcSEcCtD
Apraclonidine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000135	0.000828	CcSEcCtD
Apraclonidine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000134	0.000827	CcSEcCtD
Apraclonidine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000134	0.000826	CcSEcCtD
Apraclonidine—Malaise—Ramipril—type 2 diabetes mellitus	0.000134	0.000822	CcSEcCtD
Apraclonidine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000134	0.000822	CcSEcCtD
Apraclonidine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000133	0.000819	CcSEcCtD
Apraclonidine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000133	0.000819	CcSEcCtD
Apraclonidine—Syncope—Ramipril—type 2 diabetes mellitus	0.000133	0.000817	CcSEcCtD
Apraclonidine—Headache—Glyburide—type 2 diabetes mellitus	0.000132	0.000814	CcSEcCtD
Apraclonidine—Palpitations—Ramipril—type 2 diabetes mellitus	0.000131	0.000805	CcSEcCtD
Apraclonidine—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000131	0.000805	CcSEcCtD
Apraclonidine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00013	0.000799	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.00013	0.000799	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000129	0.000796	CcSEcCtD
Apraclonidine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000129	0.000795	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000129	0.00079	CcSEcCtD
Apraclonidine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000129	0.00079	CcSEcCtD
Apraclonidine—Pain—Irbesartan—type 2 diabetes mellitus	0.000128	0.000788	CcSEcCtD
Apraclonidine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000128	0.000788	CcSEcCtD
Apraclonidine—Insomnia—Losartan—type 2 diabetes mellitus	0.000128	0.000785	CcSEcCtD
Apraclonidine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000127	0.000781	CcSEcCtD
Apraclonidine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000127	0.000779	CcSEcCtD
Apraclonidine—Myalgia—Ramipril—type 2 diabetes mellitus	0.000126	0.000776	CcSEcCtD
Apraclonidine—Chest pain—Ramipril—type 2 diabetes mellitus	0.000126	0.000776	CcSEcCtD
Apraclonidine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000126	0.000773	CcSEcCtD
Apraclonidine—Nausea—Glyburide—type 2 diabetes mellitus	0.000126	0.000772	CcSEcCtD
Apraclonidine—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000126	0.000772	CcSEcCtD
Apraclonidine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000126	0.000772	CcSEcCtD
Apraclonidine—Somnolence—Losartan—type 2 diabetes mellitus	0.000125	0.000771	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000125	0.000771	CcSEcCtD
Apraclonidine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000125	0.00077	CcSEcCtD
Apraclonidine—Discomfort—Ramipril—type 2 diabetes mellitus	0.000125	0.000767	CcSEcCtD
Apraclonidine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000124	0.00076	CcSEcCtD
Apraclonidine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000124	0.00076	CcSEcCtD
Apraclonidine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000123	0.000759	CcSEcCtD
Apraclonidine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000123	0.000759	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000123	0.000754	CcSEcCtD
Apraclonidine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000122	0.00075	CcSEcCtD
Apraclonidine—Fatigue—Losartan—type 2 diabetes mellitus	0.000122	0.000748	CcSEcCtD
Apraclonidine—Oedema—Ramipril—type 2 diabetes mellitus	0.000121	0.000744	CcSEcCtD
Apraclonidine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000121	0.000742	CcSEcCtD
Apraclonidine—Pain—Losartan—type 2 diabetes mellitus	0.000121	0.000742	CcSEcCtD
Apraclonidine—Constipation—Losartan—type 2 diabetes mellitus	0.000121	0.000742	CcSEcCtD
Apraclonidine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.00012	0.000735	CcSEcCtD
Apraclonidine—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000119	0.000734	CcSEcCtD
Apraclonidine—Headache—Gliclazide—type 2 diabetes mellitus	0.000119	0.000731	CcSEcCtD
Apraclonidine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000119	0.000729	CcSEcCtD
Apraclonidine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000119	0.000729	CcSEcCtD
Apraclonidine—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000118	0.000725	CcSEcCtD
Apraclonidine—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000118	0.000722	CcSEcCtD
Apraclonidine—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000116	0.000715	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000115	0.000709	CcSEcCtD
Apraclonidine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000115	0.000709	CcSEcCtD
Apraclonidine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000114	0.000701	CcSEcCtD
Apraclonidine—Asthenia—Metformin—type 2 diabetes mellitus	0.000114	0.000701	CcSEcCtD
Apraclonidine—Nausea—Gliclazide—type 2 diabetes mellitus	0.000113	0.000693	CcSEcCtD
Apraclonidine—Pruritus—Metformin—type 2 diabetes mellitus	0.000112	0.000691	CcSEcCtD
Apraclonidine—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000112	0.000686	CcSEcCtD
Apraclonidine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000111	0.000682	CcSEcCtD
Apraclonidine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.00011	0.000679	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.00011	0.000678	CcSEcCtD
Apraclonidine—Dermatitis—Valsartan—type 2 diabetes mellitus	0.00011	0.000676	CcSEcCtD
Apraclonidine—Vomiting—Orlistat—type 2 diabetes mellitus	0.00011	0.000674	CcSEcCtD
Apraclonidine—Insomnia—Ramipril—type 2 diabetes mellitus	0.000109	0.000673	CcSEcCtD
Apraclonidine—Headache—Valsartan—type 2 diabetes mellitus	0.000109	0.000672	CcSEcCtD
Apraclonidine—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000109	0.000668	CcSEcCtD
Apraclonidine—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000109	0.000668	CcSEcCtD
Apraclonidine—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000109	0.000668	CcSEcCtD
Apraclonidine—Headache—Orlistat—type 2 diabetes mellitus	0.000108	0.000664	CcSEcCtD
Apraclonidine—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000108	0.000663	CcSEcCtD
Apraclonidine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000108	0.000661	CcSEcCtD
Apraclonidine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000108	0.000661	CcSEcCtD
Apraclonidine—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000106	0.000652	CcSEcCtD
Apraclonidine—Dizziness—Metformin—type 2 diabetes mellitus	0.000105	0.000646	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000104	0.000642	CcSEcCtD
Apraclonidine—Fatigue—Ramipril—type 2 diabetes mellitus	0.000104	0.000641	CcSEcCtD
Apraclonidine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000104	0.000639	CcSEcCtD
Apraclonidine—Nausea—Valsartan—type 2 diabetes mellitus	0.000104	0.000637	CcSEcCtD
Apraclonidine—Constipation—Ramipril—type 2 diabetes mellitus	0.000103	0.000636	CcSEcCtD
Apraclonidine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000103	0.000631	CcSEcCtD
Apraclonidine—Nausea—Orlistat—type 2 diabetes mellitus	0.000102	0.00063	CcSEcCtD
Apraclonidine—Asthenia—Losartan—type 2 diabetes mellitus	0.000101	0.000622	CcSEcCtD
Apraclonidine—Vomiting—Metformin—type 2 diabetes mellitus	0.000101	0.000621	CcSEcCtD
Apraclonidine—Dermatitis—Metformin—type 2 diabetes mellitus	0.0001	0.000615	CcSEcCtD
Apraclonidine—Pruritus—Losartan—type 2 diabetes mellitus	9.98e-05	0.000614	CcSEcCtD
Apraclonidine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	9.97e-05	0.000613	CcSEcCtD
Apraclonidine—Headache—Metformin—type 2 diabetes mellitus	9.95e-05	0.000612	CcSEcCtD
Apraclonidine—Dizziness—Irbesartan—type 2 diabetes mellitus	9.92e-05	0.00061	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.89e-05	0.000608	CcSEcCtD
Apraclonidine—Diarrhoea—Losartan—type 2 diabetes mellitus	9.66e-05	0.000594	CcSEcCtD
Apraclonidine—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.57e-05	0.000588	CcSEcCtD
Apraclonidine—Vomiting—Irbesartan—type 2 diabetes mellitus	9.53e-05	0.000586	CcSEcCtD
Apraclonidine—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.45e-05	0.000581	CcSEcCtD
Apraclonidine—Nausea—Metformin—type 2 diabetes mellitus	9.44e-05	0.00058	CcSEcCtD
Apraclonidine—Headache—Irbesartan—type 2 diabetes mellitus	9.39e-05	0.000577	CcSEcCtD
Apraclonidine—Dizziness—Losartan—type 2 diabetes mellitus	9.33e-05	0.000574	CcSEcCtD
Apraclonidine—Vomiting—Losartan—type 2 diabetes mellitus	8.97e-05	0.000552	CcSEcCtD
Apraclonidine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	8.91e-05	0.000548	CcSEcCtD
Apraclonidine—Nausea—Irbesartan—type 2 diabetes mellitus	8.91e-05	0.000547	CcSEcCtD
Apraclonidine—Dermatitis—Losartan—type 2 diabetes mellitus	8.89e-05	0.000546	CcSEcCtD
Apraclonidine—Headache—Losartan—type 2 diabetes mellitus	8.84e-05	0.000543	CcSEcCtD
Apraclonidine—Asthenia—Ramipril—type 2 diabetes mellitus	8.68e-05	0.000534	CcSEcCtD
Apraclonidine—Pruritus—Ramipril—type 2 diabetes mellitus	8.56e-05	0.000526	CcSEcCtD
Apraclonidine—Nausea—Losartan—type 2 diabetes mellitus	8.38e-05	0.000515	CcSEcCtD
Apraclonidine—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.28e-05	0.000509	CcSEcCtD
Apraclonidine—Dizziness—Ramipril—type 2 diabetes mellitus	8e-05	0.000492	CcSEcCtD
Apraclonidine—Vomiting—Ramipril—type 2 diabetes mellitus	7.69e-05	0.000473	CcSEcCtD
Apraclonidine—Dermatitis—Ramipril—type 2 diabetes mellitus	7.62e-05	0.000469	CcSEcCtD
Apraclonidine—Headache—Ramipril—type 2 diabetes mellitus	7.58e-05	0.000466	CcSEcCtD
Apraclonidine—Nausea—Ramipril—type 2 diabetes mellitus	7.19e-05	0.000442	CcSEcCtD
Apraclonidine—ADRA1A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.11e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX1—type 2 diabetes mellitus	1.11e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.1e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.1e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.1e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.1e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CD36—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.07e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPP2CA—type 2 diabetes mellitus	1.07e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.07e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.07e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.06e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.06e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.06e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	1.06e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.06e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.05e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.05e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.04e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.04e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.04e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	1.03e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.03e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.03e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.03e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—type 2 diabetes mellitus	1.03e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.02e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LPL—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.01e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	1.01e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARA—type 2 diabetes mellitus	1.01e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.99e-06	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	9.99e-06	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	9.99e-06	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOB—type 2 diabetes mellitus	9.98e-06	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.94e-06	0.000123	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.94e-06	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	9.86e-06	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	9.86e-06	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.82e-06	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.76e-06	0.000121	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.75e-06	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	9.75e-06	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	9.7e-06	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	9.69e-06	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	9.67e-06	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	9.59e-06	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.57e-06	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	9.55e-06	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	9.53e-06	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	9.48e-06	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	9.44e-06	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	9.43e-06	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.4e-06	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.33e-06	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	9.26e-06	0.000115	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.23e-06	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.23e-06	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	9.18e-06	0.000114	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.15e-06	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.07e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	9.06e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.06e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	9.03e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.03e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.03e-06	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	8.99e-06	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.95e-06	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.94e-06	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.86e-06	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	8.79e-06	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.78e-06	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.76e-06	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.74e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	8.73e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.72e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.69e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	8.69e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	8.68e-06	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.59e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.58e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.58e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	8.58e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	8.55e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	8.55e-06	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	8.5e-06	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.45e-06	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	8.39e-06	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	8.39e-06	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	8.35e-06	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	8.33e-06	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.33e-06	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	8.32e-06	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.31e-06	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.23e-06	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.18e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	8.18e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.16e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	8.16e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.15e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	8.15e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	8.11e-06	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.11e-06	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.07e-06	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.06e-06	9.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.02e-06	9.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	7.99e-06	9.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	7.99e-06	9.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.98e-06	9.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	7.92e-06	9.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.9e-06	9.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.82e-06	9.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	7.79e-06	9.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	7.76e-06	9.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	7.74e-06	9.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.67e-06	9.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	7.67e-06	9.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.63e-06	9.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.58e-06	9.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.53e-06	9.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	7.5e-06	9.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	7.48e-06	9.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	7.3e-06	9.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.26e-06	9e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.19e-06	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	7.16e-06	8.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	7.16e-06	8.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.15e-06	8.86e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.14e-06	8.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.13e-06	8.84e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.13e-06	8.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.13e-06	8.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.07e-06	8.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.06e-06	8.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.03e-06	8.71e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.01e-06	8.68e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	6.98e-06	8.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	6.98e-06	8.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	6.97e-06	8.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.9e-06	8.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	6.82e-06	8.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	6.76e-06	8.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.71e-06	8.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.71e-06	8.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.65e-06	8.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.63e-06	8.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	6.63e-06	8.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	6.62e-06	8.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.6e-06	8.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.6e-06	8.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	6.59e-06	8.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.58e-06	8.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.57e-06	8.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	6.55e-06	8.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.51e-06	8.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	6.49e-06	8.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	6.49e-06	8.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.41e-06	7.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.41e-06	7.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.41e-06	7.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.27e-06	7.77e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.23e-06	7.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.12e-06	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	6.08e-06	7.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	6.03e-06	7.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.98e-06	7.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.98e-06	7.41e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	5.97e-06	7.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.87e-06	7.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	5.81e-06	7.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	5.81e-06	7.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.79e-06	7.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.77e-06	7.15e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.77e-06	7.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.74e-06	7.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	5.63e-06	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	5.54e-06	6.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.49e-06	6.8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.48e-06	6.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.45e-06	6.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.44e-06	6.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.4e-06	6.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.36e-06	6.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.36e-06	6.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.33e-06	6.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	5.32e-06	6.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.23e-06	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.23e-06	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.14e-06	6.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.13e-06	6.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.09e-06	6.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.09e-06	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.08e-06	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.05e-06	6.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.98e-06	6.18e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.92e-06	6.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.86e-06	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.86e-06	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.8e-06	5.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.75e-06	5.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.74e-06	5.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.66e-06	5.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.62e-06	5.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.57e-06	5.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.48e-06	5.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.44e-06	5.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.43e-06	5.48e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.41e-06	5.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.31e-06	5.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.24e-06	5.25e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.2e-06	5.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.16e-06	5.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.15e-06	5.15e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.15e-06	5.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.13e-06	5.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.1e-06	5.08e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.07e-06	5.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.96e-06	4.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.9e-06	4.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.88e-06	4.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.87e-06	4.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.86e-06	4.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.78e-06	4.69e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.77e-06	4.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.6e-06	4.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.5e-06	4.34e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.46e-06	4.29e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.39e-06	4.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	3.29e-06	4.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.21e-06	3.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.19e-06	3.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.15e-06	3.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	2.98e-06	3.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.94e-06	3.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.75e-06	3.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.67e-06	3.31e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.61e-06	3.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.42e-06	3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.4e-06	2.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.23e-06	2.77e-05	CbGpPWpGaD
